Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Other financing activities (2023 - 2025)

Historic Other financing activities for TriSalus Life Sciences (TLSI) over the last 3 years, with Q2 2025 value amounting to $1.0 million.

  • TriSalus Life Sciences' Other financing activities fell 6031.62% to $1.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 3999.23%. This contributed to the annual value of $2.6 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that TriSalus Life Sciences reported Other financing activities of $1.0 million as of Q2 2025, which was down 6031.62% from $520000.0 recorded in Q1 2025.
  • TriSalus Life Sciences' 5-year Other financing activities high stood at $2.6 million for Q2 2024, and its period low was -$199633.0 during Q2 2023.
  • Moreover, its 3-year median value for Other financing activities was $359816.5 (2023), whereas its average is $691500.0.
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 139888.35% in 2024, then tumbled by 6031.62% in 2025.
  • TriSalus Life Sciences' Other financing activities (Quarter) stood at -$199633.0 in 2023, then skyrocketed by 103.51% to $7000.0 in 2024, then skyrocketed by 14600.0% to $1.0 million in 2025.
  • Its Other financing activities stands at $1.0 million for Q2 2025, versus $520000.0 for Q1 2025 and $7000.0 for Q4 2024.